Darzalex Royalties Fuel JNJ Rally, But Is It Too Late to Buy?

Johnson & Johnson's (JNJ) share price has been rising due to higher royalty income from Darzalex, which contributed to Genmab's strong first half revenue and full year guidance. This has sparked questions about whether the company is fully valued or if there is still upside potential.

A recent user narrative by Ben_Dur suggests that JNJ may be 11.3% overvalued at a fair value of $230.82, while Simply Wall St's DCF model indicates a future cash flow value of $364.27, with the stock trading 29.5% below that level.

This contrast highlights the mixed sentiment surrounding JNJ, with some investors weighing new drug progress, legal overhangs, and leadership changes against potential risks such as tighter regulatory scrutiny of AI evidence and rivals moving faster on differentiated platforms and data partnerships.